The Meiler Lab has long-standing collaborations with researchers and clinicians in the field of diabetes and obesity to identify genetic variants of concern for these disorders and investigates structural changes in proteins through modeling of newly identified mutations in key genes. The lab also works on drug developments efforts, e.g., through elucidating binding modes in the neuropeptide Y family and its ligands in order to design small molecule or peptide-based drugs with the ultimate goal to explore new approaches to treat complex metabolic disorders. The Meiler Lab became therefore a member of the Collaborative Research Center “Obesity Mechanisms” in Leipzig since 2021.